Averica Discovery Services, Inc., a contract research organization, with specialized expertise in small-molecule analysis and purification, has received approval by the US Drug Enforcement Administration (DEA) to handle Schedule I controlled substances.

Although not generally used in a clinical setting, Schedule I drugs are used in research in a variety of contexts. Previously, the company had been certified to work with up to Schedule II-V compounds.

Averica works with drug discovery and development teams to speed lead optimization and timelines in early development. Its services include scalable compound supply, chiral resolution, impurity isolation, and custom analytical work.

Source; Averica